128940 - Hanmi Pharm. Co., Ltd.

128940 Summary

Biopharma

Stock Price & Overview

₩473,500 +13,000 (+2.82%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩473,500 ≈ US$338 · Market cap ₩6.1tn (≈ $4.3bn)

What kstock analysis is. It reads the Korean news and the DART filing, checks the numbers against the source, and explains what changed and what to watch. It does not issue buy, sell or hold ratings and it does not set price targets. Why not »

128940 Analysis

Hanmi Pharmaceutical: The 28% Margin Arrived In One Wire Transfer

Hanmi Pharmaceutical reported a 28.1% operating margin in Q2 2026, roughly double its own three-year average, on operating profit of 131.1 billion won.

kstock researchAug 31, 1:13 AMPharmaSave

1 piece. Written with AI assistance from Korean-language sources; each links the article it rests on.

Similar to 128940

Symbol	Last Price
326030SK biopharmaceuticals Co., Ltd.	₩86,600 +0.2%
000100Yuhan Corporation	₩81,400 +0.0%
028300HLB Co., Ltd.	₩33,750 +2.9%
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.